The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.
The consortium is helping create a new era of personalized medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.
|
|
|
|
|
FNIH Biomarkers Consortium to Release Alzheimer’s Biomarker Data
CLICK HERE FOR THE RFP >>
Request for Proposals (RFP) - Developing Endpoints for Clinical Trials of Drugs for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Objective – To solicit applications from organizations with experience in developing well-defined and reliable clinical trial outcome assessments. RFP responses due on February 6, 2012.
CLICK HERE FOR THE RFP >>
Biomarkers Consortium pleased to announce Dr. Paul Deutsch, V-P, Sanofi, has been elected to fill the vacant seat on the BC's Executive Committee representing the pharmaceutical industry sector. CLICK HERE FOR DR. DEUTSCH'S BIO >>
Translational research: 4 ways to fix the clinical trial
CLICK HERE FOR ARTICLE >>
Drug Discovery News Interviews the FNIH on the Biomarkers Consortium Type 2 Diabetes Project.
CLICK HERE FOR ARTICLE >>
Biomarkers Consortium Project Aims To Develop Well-Defined Endpoints in Antibacterial Clinical Trials for Bacterial Pneumonia and Skin Infections. READ THE COMMENTARY HERE >>
